Products for Research Use Only

Berubicin

CAT: 0804-HY-14942-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14942-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Berubicin (RTA 744 free base) is a Doxorubicin analog that can cross the blood-brain barrier. Berubicin inhibits P-gp and MRP1-mediated efflux and suppresses glioblastoma multiforme (GBM). Berubicin exerts toxic effects on leukemia cells by activating nuclear factor κB (NF-κB) and induces apoptosis in neuroblastoma cells. Berubicin can be used in the study of tumors related to the nervous system[1][2][3][4][5].
CAS Number
677017-23-1
Product Name Alternative
RTA 744 (free base) ; WP 744 (free base) ; WP 769
UNSPSC
12352005
Target
Apoptosis; Caspase; NF-κB
Type
Reference compound
Related Pathways
Apoptosis; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/berubicin.html
Purity
87.76
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC1=C2C([C@@]([H])(O[C@H]3C[C@H](N)[C@H](OCC4=CC=CC=C4)[C@H](C)O3)C[C@@](C(CO)=O)(O)C2)=C(O)C5=C1C(C6=CC=CC(OC)=C6C5=O)=O
Molecular Formula
C34H35NO11
Molecular Weight
633.64
References & Citations
[1]Kazerooni R, et al. Phase I clinical pharmacokinetics of RTA 744 (berubicin (B) ), a blood-brain barrier penetrating anthracycline active against high grade glioma, and evaluation of its 13-hydroxy metabolite, berubicinol (B-ol) [J]. Molecular Cancer Therapeutics, 2007, 6 (11_Supplement) : B101-B101.|[2]Wu J, Harris NL, Inge TH. Nuclear factor-kappa B and apoptosis inducing factor activation by doxorubicin analog WP744 in SH-SY5Y neuroblastoma cells. J Surg Res. 2004 Dec;122 (2) :231-9. doi: 10.1016/j.jss.2004.05.017. PMID: 15555623.|[3]Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res. 2001 Nov-Dec;21 (6A) :3777-84. PMID: 11911247.|[4]Ashikawa K, et al. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem Pharmacol. 2004 Jan 15;67 (2) :353-64.|[5]Silberman S, et al. RTID-03. DESIGN AND INITIATION OF PIVOTAL STUDIES FOR BERUBICIN, A NOVEL, POTENT TOPOISOMERASE II POISON FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA MULTIFORME (GBM) . Neuro Oncol. 2021 Nov 12;23 (Suppl 6) :vi193.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Caspase 3; Caspase 9; NF-κB

Popular Products